New York Academy of Sciences Symposium on Advances in Adult Stem Cell Therapy in Tissue Repair for Cardiovascular Diseases to...
04 November 2011 - 12:00AM
Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of
patient-specific, expanded multicellular therapies for the
treatment of severe, chronic cardiovascular diseases, today
announced that the New York Academy of Sciences symposium "Advances
in Adult Stem Cell Therapy in Tissue Repair for Cardiovascular
Diseases" will feature researchers from Aastrom Biosciences and
other research leaders in adult stem cell therapy. The symposium
will take place at the New York Academy of Sciences at 7 World
Trade Center, 250 Greenwich St., 40th floor, New York, NY on
Wednesday, November 30, 2011, from 12:30 to 4:30 pm.
Researchers scheduled to present at the symposium include:
- Ronnda Bartel, PhD, chief scientific officer, Aastrom
Biosciences;
- Arnold I. Caplan, PhD, professor of biology and general
medicine services, Case Western Reserve University;
- Louis Messina, MD, chief of vascular and endovascular surgery,
UMass Memorial Medical Center;
- Iraklis Pipinos, MD, PhD, associate professor, department of
surgery, University of Nebraska Medical Center; and
- Sharon Watling, PharmD, vice president, clinical and
regulatory, Aastrom Biosciences.
The symposium will include updates on several recent preclinical
and clinical research programs involving the use of adult stem
cells to treat cardiovascular disease. Researchers are assessing
the ability of regenerative medicine therapies to rebuild or
restore the structure and function of damaged or diseased tissue
associated with dilated cardiomyopathy and other forms of
cardiovascular disease. A variety of autologous or allogeneic stem
cell therapies are positioned to be evaluated in pivotal,
randomized Phase 3 trials in the near future.
For more information or to register for the symposium, please
visit www.nyas.org/AdultStemCells.
About Aastrom Biosciences
Aastrom Biosciences is the leader in developing
patient-specific, expanded multicellular therapies for use in the
treatment of patients with severe, chronic cardiovascular
diseases. The company's proprietary cell-processing technology
enables the manufacture of ixmyelocel-T, a patient-specific
multicellular therapy expanded from a patient's own bone marrow and
delivered directly to damaged tissues. Aastrom has advanced
ixmyelocel-T into late-stage clinical development, including a
planned Phase 3 clinical program to study patients with critical
limb ischemia and two Phase 2 clinical trials in patients with
dilated cardiomyopathy. For more information, please visit
Aastrom's website at www.aastrom.com.
The Aastrom Biosciences, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=3663
About the New York Academy of Sciences
The New York Academy of Sciences is an independent,
not-for-profit organization committed to advancing science,
technology, and society worldwide since 1817. With 25,000 members
in 140 countries, the Academy is creating a global community of
science for the benefit of humanity. The Academy's core mission is
to advance scientific knowledge, positively impact the major global
challenges of society with science-based solutions, and increase
the number of scientifically informed individuals in society at
large. Please visit us online at www.nyas.org.
This document contains forward-looking statements, including,
without limitation, statements concerning clinical trial plans and
progress, objectives and expectations, clinical activity timing,
intended product development, the performance and contribution of
certain individuals and expected timing of collecting and analyzing
treatment data, all of which involve certain risks and
uncertainties. These statements are often, but are not always, made
through the use of words or phrases such as "anticipates,"
"intends," "estimates," "plans," "expects," "we believe," "we
intend," and similar words or phrases, or future or conditional
verbs such as "will," "would," "should," "potential," "could,"
"may," or similar expressions. Actual results may differ
significantly from the expectations contained in the
forward-looking statements. Among the factors that may result in
differences are the inherent uncertainties associated with clinical
trial and product development activities, regulatory approval
requirements, competitive developments, and the availability of
resources and the allocation of resources among different potential
uses. These and other significant factors are discussed in greater
detail in Aastrom's Annual or Transition Report on Form 10-K or
10-K/T, Quarterly Reports on Form 10-Q and other filings with the
Securities and Exchange Commission. These forward-looking
statements reflect management's current views and Aastrom does not
undertake to update any of these forward-looking statements to
reflect a change in its views or events or circumstances that occur
after the date of this release except as required by law.
CONTACT: Media contact
Andrea Coan
Berry & Company
acoan@berrypr.com
(212) 253-8881
Investor contact
Danielle Spangler
The Trout Group
dspangler@troutgroup.com
(646) 378-2924
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jul 2023 to Jul 2024